tiprankstipranks
Advertisement
Advertisement

Positive Clinical Data and Competitive Efficacy Drive Buy Rating for Revolution Medicines’ Zoldonrasib

Positive Clinical Data and Competitive Efficacy Drive Buy Rating for Revolution Medicines’ Zoldonrasib

Leerink Partners analyst Jonathan Chang has reiterated their bullish stance on RVMD stock, giving a Buy rating yesterday.

Elevate Your Investing Strategy:

Jonathan Chang has given his Buy rating due to a combination of factors, primarily centered around the promising clinical data for Revolution Medicines’ zoldonrasib. The recent presentation at the AACR 2025 Annual Meeting showcased positive dose escalation results in non-small cell lung cancer (NSCLC), with a notable overall response rate of 61% among patients treated with the recommended dose. This efficacy profile is competitive when compared to existing and emerging RAS inhibitors, highlighting zoldonrasib’s potential in the oncology landscape.
Additionally, the safety data for zoldonrasib suggests good tolerability and potential for combination with other treatments, reinforcing its viability as part of a broader therapeutic strategy. Despite the small population of NSCLC patients with KRAS G12D mutations, the data supports Revolution Medicines’ approach of developing zoldonrasib in combination with other inhibitors or standard regimens. These developments, along with upcoming data presentations, are seen as catalysts that could further enhance the company’s position in the competitive RAS inhibitor market, supporting a positive long-term outlook for the stock.

In another report released yesterday, Needham also maintained a Buy rating on the stock with a $59.00 price target.

Disclaimer & DisclosureReport an Issue

1